13D·WATCH Activist + Insider Intelligence Live feed Blog About Pilot
SCHEDULE Filed 2025-01-28 Event 2025-01-27 SEC 0000919574-25-000556 →

BROADWOOD PARTNERS, L.P. Lineage Cell Therapeutics, Inc. LCTX

Stake: 24.50% Shares: 57,848,357 CUSIP: 53566P109 Class: Common Shares, no par value

Item 4 — Purpose of Transaction

The Reporting Persons acquired their Shares for investment and are filing this Schedule 13D/A to report a change in their respective beneficial ownership percentages of the Shares and the closing of the Transaction as defined and described in the prior Schedule 13D/A (Amendment No. 27) filed by the Reporting Persons with respect to the Issuer on November 21, 2024. Pursuant to a shareholder vote held on January 27, 2025, the Issuer obtained shareholder approval for the closing of the Transaction, as described in the Form 8-K filed with the Securities and Exchange Commission by the Issuer on January 27, 2025 (the "Form 8-K"). The foregoing is a summary of certain material terms of the Form 8-K. However, such summary is not, and does not purport to be, complete and is qualified in its entirety by reference to the full text of the Form 8-K, which has been filed as Exhibit B, and is incorporated herein by reference. Mr. Bradsher serves on the Board of Directors. Except as otherwise set forth below, the Reporting Persons do not have any present plans or proposals which would relate to, or result in, the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D. However, subject to market conditions and in compliance with applicable securities laws, the Reporting Persons reserve the right, at a later date, to effect one or more of such changes or transactions in the number of Shares they may be deemed to beneficially own in open-market or privately negotiated transactions, on such terms and at such times as the Reporting Persons may deem advisable. The Reporting Persons have been and may continue to be in contact with members of the Board of Directors, other significant shareholders and others regarding alternatives and strategies that the Issuer could employ to significantly increase shareholder value over time. Among these alternatives are additional improvements to the Board of Directors and management, as well as refinements to the Issuer's strategy that may improve its business, accelerate its progress with respect to its major growth opportunities, and realize the value of its non-strategic assets. The Reporting Persons further reserve the right to act in concert with any other shareholders of the Issuer, or other persons, for a common purpose should they determine to do so, and/or to recommend courses of action to shareholders, the Board of Directors and/or the management of the Issuer.

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
1 13D/G filings on this issuer
0 other filings besides this one
Filer Track Record
3 filings by this filer
2 other filings in the data moat
Short Interest · settle 2026-03-31
DTC 22.33
25,474,080 shares short · +0.0% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers
1 holder · $266K
Point72 Asset Mgmt

Other Filings by BROADWOOD PARTNERS, L.P.

FiledFormIssuerStakeShares
2025-03-03 SCHEDULE STAAR SURGICAL CO STAA 24.30% 11,979,098 view →
2025-02-10 SCHEDULE Oncocyte Corp IMDX 40.20% 11,560,350 view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →